Now
Approved

INQOVI is the first and only once‑daily oral hypomethylating agent (HMA) treatment for adult patients with myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML).

Please see below for full Indications and Important Safety Information.